FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]

AI Summary: The FDA has granted full approval to rucaparib (Rubraca®) for treating adults with BRCA‐mutated metastatic castration‐resistant prostate cancer, converting its prior accelerated approval into standard approval. This landmark decision offers a new treatment option for patients with this genetic profile.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months

FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 5 months

FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 5 months

FDA Approves Ziftomenib for AML Treatment / 6 months

FDA updates Sarepta gene therapy label with severe warnings / 6 months

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days